CEO | Board Member | Biopharma Chief Executive leading a team dedicated to advancing the oncology treatment landscape with first-in-class innovation | MBA
For decades, oncology drug development has largely centered on the primary tumor. Yet despite billions invested, this narrow focus has not delivered the breakthroughs patients desperately need. Another Bi-specific antibody, another ADC — these can generate capital, but they don’t change the paradigm. At Novita, we’ve chosen a different path. We are advancing a first-in-class fascin inhibitor that directly targets metastasis, the true driver of mortality in cancer. By keeping our molecule distinct — rather than attaching it to a fixed cytotoxic payload — we empower clinicians with the flexibility to pair it with the therapy backbone best suited to each patient’s needs. This is not the easy route, but it is genuine innovation: complementing the battle on the primary tumors by preventing their spread and giving the immune system a stronger chance to win. Stopping metastasis remains one of oncology’s greatest unmet needs — and it is exactly where Novita intends to lead. Increase Patient survival - full stop! #Oncology #Biotech #Innovation #FascinInhibition #PatientFirst
Amazing work - patients are waiting!
Stewart Campbell this is so inspiring, and bold. Great cash flow from a great product is not always the same as bold innovation. The real litmus test will lie in the commercialization strategy and how to build the case with physicians across academic and community practices.
Senior Corporate Account Director at Ipsen
1moHope you are well.